We recently read an article published in Advanced Materials Interfaces, “Polymer Co-Coating of Gold Nanoparticles Enables Their Integration Into Contact Lenses for Stable, Selective Ocular Light Filters,” by Clasky et al., 2022. We found that article to be of considerable interest. This new technology for tuning the spectral filtering properties of contact lenses is intriguing and might indeed be developed into anti-myopia therapies. However, we feel that the statement “Chronic exposure to long-wavelength (red) light is associated with increased incidence and progression of myopia in preclinical models” ignores important inter-species differences in the response to removing red light and may mislead readers into thinking that filtering out long wavelength (red) light will slow myopia in children. In fact, the current evidence from primate and close-to-primate animal models strongly suggests the opposite: that it is blocking short wavelength light (less than 500nm) that has anti-myopic properties.
In some species, red light exposure promotes myopia (chickens [1] guinea pigs [2] and fish [3]) and is consistent with the authors’ suggestion that blocking red light might be anti-myopiagenic. However, exposure to long wavelength red light produces a powerful and consistent anti-myopia effect in both the rhesus monkey [4] and the closely-related diurnal tree shrew [5]. More recently, it was shown that amber light, spanning a relatively broad band of frequencies but omitting those shorter than 500 nm, also promotes hyperopia in tree shrews [6]. Although the reason for the inter-species differences is not yet known, the data from animals close to humans suggest that blocking the blue, rather than the red wavelengths, is more likely to prevent myopia progression.
References
- [1].a) Seidemann A, Schaeffel F, Vision Res 2002, 42, 2409; [DOI] [PubMed] [Google Scholar]; b) Rucker FJ, Wallman J, Vision Res 2009, 49, 1775; [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Wildsoet CF, Howland HC, Falconer S, Dick K, Vision Res 1993, 33, 1593. [DOI] [PubMed] [Google Scholar]
- [2].a) Liu R, Qian YF, He JC, Hu M, Zhou XT, Dai JH, Qu XM, Chu RY, Exp Eye Res 2011, 92, 447; [DOI] [PubMed] [Google Scholar]; b) Long Q, Chen D, Chu R, Cutan Ocul Toxicol 2009, 28, 176; [DOI] [PubMed] [Google Scholar]; c) Qian YF, Liu R, Dai JH, Chen MJ, Zhou XT, Chu RY, J Vis 2013, 13; [DOI] [PubMed] [Google Scholar]; d) Zou L, Zhu X, Liu R, Ma F, Yu M, Liu H, Dai J, J Ophthalmol 2018, 2018, 9197631. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [3].a) Kroger RH, Fernald RD, Vision Res 1994, 34, 1807; [DOI] [PubMed] [Google Scholar]; b) Kroger RH, Wagner HJ, J Comp Physiol A 1996, 179, 837. [DOI] [PubMed] [Google Scholar]
- [4].a) Smith EL 3rd, Hung LF, Arumugam B, Holden BA, Neitz M, Neitz J, Invest Ophthalmol Vis Sci 2015, 56, 6490; [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Hung LF, Arumugam B, She Z, Ostrin L, Smith EL 3rd, Exp Eye Res 2018, 176, 147. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [5].a) Gawne TJ, Ward AH, Norton TT, Vision Res 2017, 140, 55; [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Ward AH, Norton TT, Huisingh CE, Gawne TJ, Vision Res 2018; [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Gawne TJ, Siegwart JT Jr., Ward AH, Norton TT, Exp Eye Res 2017, 155, 75. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [6].Khanal S, Norton TT, Gawne TJ, Ophthalmic Physiol Opt 2021, 41, 1076. [DOI] [PMC free article] [PubMed] [Google Scholar]